Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

15.3K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.3K
T Cell Types and Functions01:24

T Cell Types and Functions

1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

310
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
310
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.3K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.7K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

342
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
342

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.

The Journal of allergy and clinical immunology·2026
Same author

Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA).

Respiratory research·2026
Same author

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA.

BMJ open respiratory research·2026
Same author

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

ERJ open research·2026
Same author

First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor.

The Journal of allergy and clinical immunology·2026
Same author

A novel SPECT-CT imaging platform for quantifying <i>in vivo</i> lung cytokine signals in COPD.

ERJ open research·2025

Related Experiment Video

Updated: Dec 1, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.7K

Regulation of inflammatory cell function by corticosteroids.

Maria G Belvisi1

  • 1Respiratory Pharmacology Group, Faculty of Medicine, Imperial College London, National Heart & Lung Institute, Guy Scadding Building, Dovehouse Street, London SW3 6LY, UK. m.belvisi@Imperial.ac.uk

Proceedings of the American Thoracic Society
|August 23, 2005
PubMed
Summary

Inflammatory cell differences in asthma and COPD impact treatment effectiveness. Glucocorticoids work better for asthma due to varying inflammatory cell sensitivity, unlike in COPD.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K
Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses
06:43

Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses

Published on: March 29, 2017

10.2K

Related Experiment Videos

Last Updated: Dec 1, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.7K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K
Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses
06:43

Increased Recovery Time and Decreased LPS Administration to Study the Vagus Nerve Stimulation Mechanisms in Limited Inflammatory Responses

Published on: March 29, 2017

10.2K

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Cell Biology

Background:

  • Asthma and Chronic Obstructive Pulmonary Disease (COPD) exhibit distinct lung inflammatory profiles.
  • Key mediators in asthma include tumor necrosis factor-alpha, interleukin (IL)-1beta, and type 2 T-helper cell cytokines (IL-4, IL-5, IL-13).
  • COPD is characterized by CD8(+) T lymphocytes, macrophages, and neutrophils.

Purpose of the Study:

  • To investigate the differential inflammatory cell profiles in asthma and COPD.
  • To explore the varying sensitivities of inflammatory cells to glucocorticoids.
  • To understand how these differences affect treatment outcomes, particularly for inhaled corticosteroid therapy.

Main Methods:

  • Comparative analysis of inflammatory cell types in asthma and COPD lung tissues.
  • Review of the known effects of glucocorticoids on various inflammatory cells.
  • Correlation of inflammatory cell profiles and glucocorticoid sensitivity with treatment responses.

Main Results:

  • Asthma involves eosinophils, mast cells, basophils, and specific T-helper cells, which are generally responsive to glucocorticoids.
  • COPD involves neutrophils and macrophages, with evidence suggesting lower sensitivity to glucocorticoids compared to asthma-related cells.
  • Glucocorticoids inhibit eosinophils, neutrophils, mast cells, basophils, and macrophages, but differential sensitivity exists.

Conclusions:

  • Differences in inflammatory cell populations and their glucocorticoid sensitivity contribute to the varied efficacy of inhaled corticosteroids in asthma versus COPD.
  • Understanding these cellular and molecular distinctions is crucial for developing targeted therapies for obstructive lung diseases.